Is BEAM a buy according to AI stock analysis?

BEAM AI stock analysis does not issue a personalized buy recommendation. Beam Therapeutics has a differentiated base editing platform, a maturing pipeline, and cash runway into mid-2029, but it remains pre-profitable with significant cash burn, high volatility, a July 2026 arbitration ruling that favored Prime Medicine on PM647, and binary clinical risks. The stock carries roughly 23.5% short interest and a consensus Moderate Buy rating from analysts.

What is the BEAM AI stock forecast?

The BEAM AI stock forecast is a scenario range, not a promised target. The scenario framework around the $25.92 cutoff price estimates a bullish range of $45 to $70, a base case of $26 to $45, and a bearish case of $15 to $26, depending on clinical trial outcomes, risto-cel BLA progress, PM647 competition, partnership developments, and cash runway.

What technical levels matter for BEAM?

The main BEAM technical levels are the $24.67 to $25.07 support zone (recent low and the low end of the 50-day range), the critical $15.60 support at the 52-week low, and resistance at $28 to $30 and $37.92 to $38.26 (50-day range high and 52-week high). A sustained break below $24.67 would weaken the technical setup significantly.

Can AI predict BEAM stock price?

No, AI cannot reliably predict stock prices. AI can organize financial data, calculate scenarios, and provide research context, but unexpected clinical trial results, patent rulings, regulatory decisions, competitive developments, and market conditions can invalidate any forecast, especially for pre-profit biotechnology stocks.

How should I use this BEAM AI trading strategy?

Use the BEAM AI trading strategy as a rules-based research framework, not personal financial advice. Define the setup, position size, risk limit, monitoring data, and invalidation condition before acting. Given the very high volatility (beta of 2.18) and binary event risk of biotech stocks, position sizing and risk management are particularly important.

What is base editing and why does it matter for BEAM?

Base editing is a precision gene-editing technology that makes single-nucleotide changes in DNA without creating double-strand breaks, unlike traditional CRISPR/Cas9. BEAM was co-founded by David Liu, a pioneer of base editing. If successfully developed into approved therapies, base editing could offer safer and more precise treatment for a wide range of genetic diseases.

What was the outcome of the Prime Medicine arbitration?

In July 2026, Prime Medicine announced a positive, binding resolution of its arbitration with Beam Therapeutics over the parties' 2019 Collaboration and License Agreement, confirming PM647 in alpha-1 antitrypsin deficiency belongs in Prime's program. Prime shares rose after the announcement, while BofA reiterated a Buy rating on BEAM with a $47 target and said the impact on Beam is limited. The financial and operational impact depends on how the AATD competitive field develops.

When does Beam expect to submit a BLA for risto-cel?

Beam expects to submit a Biologics License Application for risto-cel, its sickle cell disease candidate, as early as year-end 2026. The decision is supported by BEACON Phase 1/2 data published in the New England Journal of Medicine in April 2026, which showed deep resolution of sickle cell disease markers and rapid engraftment.

Beam Therapeutics Inc. research snapshot

BEAM AI Stock Analysis

BEAM AI stock analysis currently reads Beam Therapeutics Inc. as a pioneering precision genetic medicine company built on its base editing platform, which makes single-nucleotide changes in DNA without double-strand breaks. The stock traded at $25.92 on August 3, 2026, implying about $2.66 billion of equity value using 102.88 million shares. The company held $1.2 billion in cash and marketable securities at the end of the first quarter of 2026 against roughly $250.82 million in total debt, with management guiding that its cash runway extends into mid-2029. TTM revenue is approximately $164 million (primarily collaboration revenue) with a TTM net loss of roughly $66 million. Recent developments include publication of the BEACON trial data for risto-cel in the New England Journal of Medicine, a plan to submit a BLA for risto-cel as early as year-end 2026, selection of a 60 mg dose for BEAM-302 with a pivotal cohort expected in the second half of 2026, FDA clearance of the BEAM-304 IND for PKU in June 2026, and a positive binding arbitration resolution for Prime Medicine over PM647 in AATD that BofA viewed as having limited impact on BEAM. The main debate is whether the clinical pipeline can convert into approved products, whether competition and the Prime Medicine dispute constrain the platform, and whether the stock can break out of its recent downtrend despite roughly 23% short interest. This page is informational research and is not investment advice.

Current price

$25.92 on August 3, 2026

Market cap

$2.66 billion using 102.88 million shares; price times shares verified to about $2.67 billion

AI score

43 / 100

Rating

Pioneering base editing platform with a maturing clinical pipeline (risto-cel, BEAM-302, BEAM-304) and cash runway into mid-2029, offset by pre-profitability, significant cash burn, about 23.5% short interest, a July 2026 arbitration ruling that favored Prime Medicine on PM647, and binary clinical outcomes

Trend status

Price at $25.92 sits near the low end of the 50-day range ($25.07 to $37.92) after a sharp pullback; roughly 26% lower over the past month, down about 7% year to date, with high volatility and beta near 2.18

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. BEAM has a public history since its 2020 IPO, SEC filings, clinical trial disclosures, and partnership agreements with Pfizer, Verve, and Orbital. However, as a pre-profit biotech with no approved products, revenue and earnings history is limited and forward value depends on clinical binary outcomes and platform differentiation.
bias Check: The main AI bias risk is overstating the platform value because of the elegant base editing technology (co-founded by David Liu, a pioneer in the field) while underestimating commercialization challenges, the impact of the Prime Medicine arbitration that resolved in favor of Prime on PM647, competition from CRISPR/Cas9 and prime editing approaches, dilution risk, and the high failure rate of clinical-stage biotech.
ai Confidence: High for cash position, share count, market-cap math, debt, and reported financials as of the most recent filings. Medium for pipeline probability-adjusted value, clinical adoption trajectory, and twelve-month price scenarios because these depend on clinical data and competitive dynamics that cannot be predicted with precision.
investment Certainty: Low to medium. BEAM has a differentiated platform, a maturing pipeline, and a long cash runway, but the path to sustained profitability is long, binary clinical risks remain, a key arbitration was recently resolved against the company on PM647, and the stock carries high volatility and elevated short interest.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Beam Therapeutics develops precision genetic medicines using its base editing platform, which makes targeted single-nucleotide changes in DNA without double-strand breaks. The pipeline spans ex vivo HSC therapy risto-cel for sickle cell disease, in vivo liver-directed programs BEAM-302 for AATD, BEAM-304 for PKU, and BEAM-301 for GSDIa, plus the ESCAPE platform for antibody-based conditioning.	Medium
Moat	The moat comes from foundational base editing intellectual property co-developed by David Liu and collaborators at the Broad and Whitehead Institutes, deep scientific expertise, first-mover status in base editing, and strategic partnerships with Pfizer, Verve, and Orbital. However, the July 2026 arbitration that resolved in favor of Prime Medicine on PM647 creates AATD competitive risk, and competing platforms (CRISPR/Cas9, prime editing, other base editing variants) keep the field contested.	Medium
Management	CEO John M. Evans, MBA, leads BEAM and previously served in senior roles at other biotech companies. Co-founder David R. Liu remains a scientific adviser. Management has delivered key clinical milestones, including BEACON data published in NEJM, BEAM-302 topline data with a 60 mg dose selected, FDA clearance of the BEAM-304 IND, and a financing with Sixth Street. Insider selling of about $10.47 million in the past three months is a concern, and the key test remains clinical execution and capital allocation discipline as cash burn continues.	Medium
Financial trend	The company is pre-profit with TTM revenue of about $164 million (largely collaboration revenue) and a TTM net loss of roughly $66 million. Operating cash burn was roughly $370 million on a TTM basis, and free cash flow was negative. The $1.2 billion cash position extends the runway into mid-2029, but continued losses mean the company may eventually need additional capital or profitability to avoid dilution.	High
Valuation	At $25.92, the stock trades at a market cap of about $2.66 billion. With negative GAAP earnings, traditional P/E is not applicable. Enterprise value of about $1.7 billion (market cap minus net cash of roughly $960 million) prices in pipeline optionality. The stock trades at roughly 2.1x book value and about 16x TTM revenue. The MarketBeat consensus price target of $46.85 suggests about 81% upside from the current price.	Medium
Technical trend	Price at $25.92 sits near the low end of the 50-day range ($25.07 to $37.92) after a sharp pullback of roughly 26% over the past month. The 52-week range is $15.60 to $38.26, and beta near 2.18 indicates very high volatility. Year-to-date performance is roughly down 7%.	Medium
Risk level	Risk is high. Pre-profitability, binary clinical outcomes, the July 2026 arbitration that favored Prime Medicine on PM647, elevated cash burn, roughly 23.5% short interest, very high beta of 2.18, insider selling, and competitive pressure from gene-editing platforms all contribute. Dilution risk exists as the company may need to raise capital in the future.	High
AI confidence	Data confidence is high for balance sheet items, share count, market-cap verification, and reported financials, but lower for pipeline probability-adjusted valuation, BEAM-302 and BEAM-304 peak sales estimates, and long-term price scenarios.	Medium data confidence
Investment certainty	Investment certainty is low to medium. BEAM has a differentiated base editing platform and multiple near-term catalysts, but the company is not yet profitable, the Prime Medicine arbitration created AATD competition, clinical and commercial execution is unproven, and the stock carries high volatility that may not suit all investors.	Low to medium

BEAM AI stock forecast

BEAM AI Stock Forecast Scenarios

The BEAM AI stock forecast uses a scenario framework around the $25.92 cutoff price. Because BEAM has negative EPS, traditional P/E-based scenario models are not applicable. The scenarios below are qualitative framework estimates based on pipeline progress, partnership developments, clinical data readouts, cash position, and analyst consensus, not promises or recommendations.

Bullish case

$45 to $70

More likely if risto-cel BLA submission and review progress, the BEAM-302 pivotal cohort reports positive data, BEAM-304 reaches clinical proof of concept in PKU, the ESCAPE platform advances, partnership milestones from Pfizer or Verve materialize, and short interest decreases. Analysts including HC Wainwright ($80 target), Canaccord ($74), Citi ($68), and Wedbush ($65) see substantial upside, and StockAnalysis reports a $52.31 consensus target.

Base case

$26 to $45

More likely if pipeline candidates advance without major surprises, the Prime Medicine arbitration impact stays limited as BofA expects, cash burn remains manageable within the mid-2029 runway, and the stock trades in line with the MarketBeat consensus target of $46.85 with normal biotech volatility and periods of share-price weakness.

Bearish case

$15 to $26

More likely if the PM647 competition in AATD intensifies, clinical trials disappoint or are delayed, risto-cel BLA timing slips, cash burn accelerates requiring dilutive financing, or the stock is pressured by sustained short interest, insider selling, and risk-off sentiment in biotech. Barclays holds a $21 low price target, and the 52-week low is $15.60.

BEAM AI technical analysis

BEAM AI Technical Analysis

BEAM AI technical analysis uses public market data available at the August 3, 2026 cutoff. The latest price was $25.92 on August 3, 2026, after a prior close of $25.52 on July 31, 2026. MarketBeat reported a 50-day range of $25.07 to $37.92, a 52-week range of $15.60 to $38.26, and beta near 2.18. Technical levels describe market structure and do not predict the next price move.

Level	Value	Why it matters
Current price	$25.92	Latest price used for this page, dated August 3, 2026; prior close was $25.52 on July 31, 2026.
Near support	$24.67 to $25.07	The recent trading low and the lower end of the 50-day range form the first support band.
Key support	$15.60	The 52-week low is a critical support level. A break below this would indicate significant technical weakness.
Near resistance	$28 to $30	The round-number zone and prior price congestion create the first overhead resistance band.
Key resistance	$37.92 to $38.26	The 50-day range high and the 52-week high form the next major reference zone if price reclaims the mid-30s.
50-day moving average	Price below the average	Price sits near the bottom of the 50-day range, indicating a weak short-term trend as of the August 3, 2026 data snapshot.
Momentum	Negative over the past month	The stock fell roughly 26% in the last month, so momentum is currently weak; a sustained move back above $28 would improve the picture.
Volume	About 0.8 to 0.9 million shares on August 3, 2026	Volume was below the roughly 2.1 million share average, suggesting limited participation during the recent decline.
Volatility	52-week range $15.60 to $38.26; beta near 2.18	The wide annual range and very high beta make position sizing and predefined risk limits essential for any trading framework.
Invalidation	A sustained close below $24.67	A decisive break below the recent low would signal further downside toward the $21 area and eventually the 52-week low near $15.60.

BEAM AI trading strategy

BEAM AI Trading Strategy Framework

The BEAM AI trading strategy is a rules-based framework, not personalized advice. Pair price action with clinical data readouts, risto-cel BLA milestones, BEAM-302 pivotal cohort progress, arbitration and competition updates, cash runway disclosures, analyst ratings, and short interest trends.

Trend-following setup

Consider a trend-following framework only after price reclaims and holds above the $28 to $30 resistance zone, confirmed by above-average volume, positive clinical data readouts, or favorable regulatory milestones.

A close back below the $25 area reduces confidence. A sustained close below $24.67 or the 52-week low at $15.60 invalidates the setup.

Mean-reversion setup

If price tests the $24.67 to $25.07 support zone while the company maintains its cash position and clinical pipeline remains on track, the risk/reward may favor a mean-reversion framework. However, biotech mean-reversion carries binary gap-down risk on negative news.

Do not average down automatically if the Prime Medicine dispute escalates, cash burn accelerates, clinical trials fail or slip, or financing terms are dilutive. Biotech stocks can gap down significantly on binary news events.

Event-driven monitor

Track the Q2 2026 earnings release expected in early August 2026, the BEAM-302 updated data presentation at ERS 2026 with an investor webcast on September 8, 2026, risto-cel BLA timing, BEAM-304 progress, PM647 competitive updates, cash runway, and short interest changes. Major events can produce outsized moves given the 2.18 beta.

Reduce position size before binary clinical data events or regulatory announcements. A failed trial or adverse ruling can destroy a large share of market value overnight.

Investment research summary

Four-master Research Compression

Business essence

Beam Therapeutics sells precision genetic medicines built on its base editing technology, which makes single-nucleotide changes in DNA without double-strand breaks. Customers are patients with serious genetic diseases. The company is funded through partnership collaboration revenue and potential future product revenues. The business model is high-risk, high-reward biotech drug development.

Moat

The moat rests on foundational base editing IP, first-mover advantage in base editing, and strategic partnerships with Pfizer, Verve, and Orbital. However, the July 2026 arbitration that resolved in favor of Prime Medicine over PM647 creates AATD competitive risk, and competing platforms (CRISPR/Cas9, prime editing) keep the field contested.

Munger risk inversion

The thesis fails if PM647 competition in AATD limits BEAM-302 market opportunity, if risto-cel or BEAM-302 clinical candidates fail or slip, if BEAM-304 proof of concept disappoints, if cash burn requires dilutive financing, if Pfizer or Verve deprioritize partnerships, or if competitors with superior editing technologies leapfrog base editing.

Management

CEO John M. Evans has led the company and brings biotech leadership experience. Co-founder David R. Liu provides scientific vision. Management has delivered key milestones, including BEACON data in NEJM, BEAM-302 topline data, BEAM-304 IND clearance, and a Sixth Street financing. The key test is clinical execution and capital allocation as the company approaches commercial-stage status. Insider selling of approximately $10.47 million in recent months is worth monitoring.

Industry trend

Precision gene editing represents a potential paradigm shift in medicine. Base editing, as a more precise alternative to traditional CRISPR/Cas9, is at the forefront of next-generation gene editing. The field has attracted significant investment, partnerships, and scientific talent. However, intense competition and rapid technological change mean no platform has a guaranteed lead.

Valuation and margin of safety

At $25.92, BEAM trades at a market cap of about $2.66 billion with negative earnings. The enterprise value of about $1.7 billion (net of roughly $960 million in net cash) prices in pipeline optionality. Margin of safety is limited given pre-profitability, binary risks, roughly 23.5% short interest, and AATD competition from Prime Medicine. The MarketBeat consensus target of $46.85 suggests upside, but downside toward the $21 to $26 range is possible in a bear scenario.

Source-backed data

BEAM Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
Current price	$25.92 on August 3, 2026; prior close $25.52 on July 31, 2026	MarketBeat and StockAnalysis	August 3, 2026
Shares outstanding	102.88 million shares	MarketBeat	August 3, 2026
Market capitalization	$2.66 billion reported, verified at about $2.67 billion using $25.92 x 102.88 million shares	MarketBeat and financial rigor market-cap verification	August 3, 2026
TTM revenue and net income	$164.01 million revenue and about -$66 million net loss (TTM)	StockAnalysis and Yahoo Finance	August 3, 2026
Cash and total debt	$1.2 billion cash, cash equivalents and marketable securities (March 31, 2026) and $250.82 million total debt	Beam Q1 2026 press release and StockAnalysis	August 3, 2026
Cash runway	Into mid-2029	Beam Q1 2026 press release	August 3, 2026
Enterprise value	About $1.7 billion (market cap minus net cash)	Computed from reported cash and debt figures	August 3, 2026
TTM EPS	-$0.68 per share (MarketBeat TTM); -$0.64 (StockAnalysis)	MarketBeat and StockAnalysis	August 3, 2026
Price-to-book ratio	2.12x (MarketBeat); 2.25x (Yahoo Finance quarterly)	MarketBeat and Yahoo Finance	August 3, 2026
Price-to-sales ratio	16.22x TTM (MarketBeat); 15.98x TTM (Yahoo Finance)	MarketBeat and Yahoo Finance	August 3, 2026
Technical snapshot	50-day range $25.07 to $37.92, 52-week range $15.60 to $38.26, beta 2.18	MarketBeat statistics	August 3, 2026
Short interest	23.46% of float; 8.93 days to cover	MarketBeat	August 3, 2026
Consensus analyst rating	Moderate Buy with $46.85 average price target (14 analysts, MarketBeat); Strong Buy with $52.31 target (StockAnalysis, 15 analysts)	MarketBeat and StockAnalysis	August 3, 2026
Q1 2026 earnings	Revenue $31.74 million (up about 325% YoY); EPS -$0.91 (beat the -$1.03 estimate)	MarketBeat and Beam Q1 2026 press release	August 3, 2026
Risto-cel (BEAM-101) milestone	BEACON Phase 1/2 data published in the New England Journal of Medicine in April 2026; BLA submission expected as early as year-end 2026	Beam press releases	August 3, 2026
BEAM-302 (AATD) milestone	60 mg selected as optimal biological dose; pivotal cohort expected in the second half of 2026; updated data at ERS Congress 2026 with webcast September 8, 2026	Beam press releases	August 3, 2026
BEAM-304 (PKU) milestone	FDA cleared the IND application for BEAM-304 on June 18, 2026	Beam press release	August 3, 2026
Prime Medicine arbitration	Positive, binding arbitration resolution announced in July 2026 in favor of Prime Medicine over PM647 in AATD; BofA reiterated Buy with a $47 target and viewed the impact on BEAM as limited	Yahoo Finance and StockAnalysis news	August 3, 2026
CEO	John M. Evans, MBA (CEO)	MarketBeat and Beam Therapeutics website	August 3, 2026

Frequently Asked Questions

Read the CRSP AI stock analysis Read the DNLI AI stock analysis Read the VRTX AI stock analysis Build an AI trading strategy

This BEAM page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are conditional scenarios based on available data and assumptions. Biotech investments carry high risk, including binary clinical outcomes, patent litigation and arbitration uncertainty, regulatory risk, and potential capital dilution. Data can be delayed, incomplete, or wrong. Verify all information from original filings and consult a qualified financial advisor before making investment decisions.